Oura's ring-to-platform bet reaches its S-1: $1.2B revenue, $16B IPO target

Oura, founded in Finland in 2013, makes smart rings priced at $350–$400 that measure sleep, activity, readiness and other biometrics; paired with an app and a paid membership for deeper health metrics, the product is marketed as an always-on health intelligence platform.

That a ring people would wear day and night could capture continuous biometrics and grow from a $350 hardware sale into a subscription health-data platform.

Founded in Finland in 2013, Oura set itself apart from Fitbit, Garmin and Apple Watch with a sleek, unobtrusive ring that tracks activity, sleep and daily readiness. The product started in the niche of biohacking CEOs and performance-minded early adopters before widening into a mainstream sleep-and-recovery brand.

Revenue scaled from $500M in 2024 to roughly $1B in 2025, with close to $2B expected in 2026. In September 2025 Oura had sold 5.5M rings to date and closed an $875M Series E at about an $11B valuation, with backers including Fidelity, ICONIQ, Whale Rock and Atreides; it confidentially filed for an IPO in May 2026. The company now has more than 900 employees and offices including San Francisco, and faces a proposed class action (filed August 2026 by Clarkson Law Firm) alleging its sleep staging is little more reliable than a coin flip — claims Oura disputes.

On 2026-09-03 Oura publicly filed its S-1 with the SEC. The filing showed revenue of $1.2B for the nine months ended 2026-06-30, up from $697M a year earlier, and reported selling 3.6M rings over the past year with about 5M paid members. Bloomberg reported the company was expected to seek a valuation above $16B, with the offering reportedly planned to raise up to $3B — though no price had been set as of 2026-09-05.

The ring is the wedge: unobtrusive enough to sleep in, it captures continuous biometrics that wrist devices miss, making the subscription data valuable.

Membership economics: roughly 5M paid members with about 85% twelve-month retention turned a one-time hardware sale into recurring revenue that roughly doubled year over year.

A widening audience: starting with biohacking CEOs, Oura became a mainstream sleep-and-recovery brand as the wearable category filled with rivals.

The data moat: about 42 billion hours of longitudinal biometrics underpins AI features and the S-1 pitch to health plans, employers and care providers.

Going public while hot: after the September 2025 Series E at about $11B, a reported valuation above $16B converts growth into a large liquid outcome.

Bet on the form people keep on: Oura's ring captured sleep biometrics wrist wearables missed, and the data platform that followed reached a $1.2B run toward a reported $16B IPO.

As of 2026-09-05 Oura is still private with more than 900 employees, but its S-1 is public and the IPO is the next milestone; Bloomberg-reported figures point to a raise of up to $3B at a valuation above $16B. The registration statement pitches expansion beyond fitness into clinical evidence, health plans, employers and care providers, powered by a dataset Oura puts at nearly 42 billion hours of physiological data across more than 50 health metrics. The proposed sleep-accuracy class action remains pending, and Oura says it will defend against the claims.